Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PRELUDE THERAPEUTICS INC
NASDAQ:PRLD (2/11/2025, 3:19:47 PM)
0.93
-0.16 (-14.68%)
PRLD Latest News and Analysis
a day ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
